May 11, 2025
Zepbound (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in complete SURMOUNT-5 results published in The New England Journal of Medicine
May 09, 2025
Lilly plans to expand Purdue University collaboration with up to a $250 million investment to accelerate pharmaceutical innovation
May 08, 2025
Lilly announces transitions in executive leadership
May 05, 2025
Lilly declares second-quarter 2025 dividend
May 02, 2025
Lilly to participate in Bank of America Securities 2025 Healthcare Conference
May 01, 2025
Lilly reports first-quarter 2025 financial results and highlights pipeline momentum
Apr 17, 2025
Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial
Apr 17, 2025
Lilly confirms date and conference call for first-quarter 2025 financial results announcement
Mar 30, 2025
Lilly's lepodisiran reduced levels of genetically inherited heart disease risk factor, lipoprotein(a), by nearly 94% from baseline at the highest tested dose in adults with elevated levels
Mar 27, 2025
LillyDirect platform expands to facilitate access to Alzheimer's disease care
Mar 07, 2025
Lilly's EBGLYSS® (lebrikizumab-lbkz) single monthly maintenance injection achieved completely clear skin at three years in half of patients with moderate-to-severe atopic dermatitis
Feb 28, 2025
Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with a BTK inhibitor
Feb 28, 2025
Lilly to participate in Leerink Partners Global Healthcare Conference
Feb 26, 2025
Lilly plans to more than double U.S. manufacturing investment since 2020 exceeding $50 billion
Feb 25, 2025
Lilly launches additional Zepbound vial doses and offers new savings for self-pay patients
Feb 18, 2025
Lilly to participate in TD Cowen's 45th Annual Health Care Conference
Feb 07, 2025
Most patients on Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease achieved sustained clinical remission and endoscopic response at two years
Feb 06, 2025
Lilly reports full Q4 2024 financial results and provides 2025 guidance
Jan 23, 2025
Lilly confirms date and conference call for fourth-quarter 2024 financial results and 2025 financial guidance announcement
Jan 14, 2025
Lilly provides update on 2024 revenue guidance, announces 2025 revenue guidance